Zamtocabtagene autoleucel for relapsed or refractory diffuse large B-cell lymphoma after at least 2 therapies

Zamtocabtagene autoleucel is currently in clinical development for adults with relapsed or refractory diffuse large B cell lymphoma (DLBCL) after receiving at least two lines of therapy. DLBCL is a cancer of B cells (a type of immune cell) and the most common type of fast-growing non-Hodgkin’s lymphoma (NHL). In DLBCL, the body makes abnormal B cells which build up in lymph nodes or other body organs. The affected cells start to divide constantly before they are fully mature and lose their infection-fighting properties, which makes the body more vulnerable to infection. Relapsed or refractory DLBCL refers to the disease reappearing after a period of remission or when the lymphoma becomes non-responsive to treatment. There is a high incidence of disease relapse or becoming refractory after treatment with currently available therapies.